Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy franchises and mental health moonshots, the M&A tape is starting to read like a sector-wide restocking plan—with a punchline that’s very serious for investors.
The Week’s Headliners in White Coats
Several sizeable buyouts and signings hit the tape this week, spanning oncology, immunology, autoimmune disease and neuroscience. While the fine print varies, the common thread is large-cap pharma paying up for late‑stage or near‑proof‑of‑concept assets that can move the revenue needle before the looming patent cliff takes too big a bite.
- Novartis (NVS) agreed to acquire Excellergy, a private U.S. biotech focused on next-generation allergy therapies, in a deal worth up to roughly $2–3 billion including milestones, securing lead anti‑IgE antibody EXL‑111 now in early clinical development.
- Merck (MRK) struck a roughly $6.7 billion agreement to buy Terns Pharmaceuticals (TERN), adding BCR‑ABL1 inhibitor TERN‑701 and other oncology assets at what analysts describe as one of the leaner deal premiums seen since 2018.
- Otsuka Pharmaceutical (OTSKY) moved to acquire Transcend Therapeutics for up to $1.225 billion, including about $700 million in upfront cash, bringing in a private CNS-focused biotech platform with late‑stage aspirations in psychiatric and neurological disorders.
Novartis Doubles Down on Allergies
Novartis’ move on Excellergy looks like a textbook “buy the growth you can’t afford to wait for” transaction, targeted squarely at IgE‑driven allergic disease. The company gains Excellergy’s lead asset EXL‑111, a high‑affinity, half‑life‑extended anti‑IgE antibody designed for faster, more durable suppression of allergic responses—think fewer flare‑ups, more days when patients can picnic without a medical contingency plan.
- The deal value is framed at up to $2–3 billion including milestones, a level that signals Novartis’ confidence in allergy as a durable growth franchise rather than a niche add‑on.
- Strategically, it deepens Novartis’ immunology and allergy pipeline at a time when large pharma is racing to bulk up differentiated biologics ahead of a multiyear patent cliff.
Merck’s Terns Deal: A Modest Premium, Serious Intent
If Novartis played the bold allergy card, Merck opted for understated aggression with its agreement to buy Terns Pharmaceuticals. The roughly $6.7 billion price tag comes with what has been called the lowest recorded premium for a biotech buyout since 2018, a reminder that in this market, leverage sometimes wears a lab coat and a calculator.
- Central to the deal is TERN‑701, a BCR‑ABL1 tyrosine kinase inhibitor aimed at hematologic malignancies, which Merck can plug into its already formidable oncology infrastructure.
- The valuation has fueled debate, with some analysts arguing the sticker does not fully capture the long‑term potential of TERN‑701—an argument Merck appears happy to test in the clinic rather than on message boards.
Otsuka’s Transcend Moment in CNS
Otsuka Pharmaceutical’s acquisition of Transcend Therapeutics adds another notable ticket to this week’s biotech buyout roll, this time in central nervous system disorders. The deal, valued at up to $1.225 billion with about $700 million upfront, gives Otsuka access to a private pipeline built around novel psychiatry and neurology candidates at a time when CNS innovation is finally escaping the “too hard” bucket for big pharma.
- For Transcend’s backers, the structure—significant cash upfront plus milestones—offers both a liquidity event and continued upside if late‑stage trials cooperate.
- For Otsuka, the transaction reinforces a long‑running strategy in mental health, effectively adding another shot on goal in a therapeutic area where unmet need remains stubbornly high and pricing power, if differentiation is proven, can be unusually resilient.
What This Week’s Deals Signal for Biotech
Taken together, this week’s buyouts highlight how large-cap pharma is leaning into targeted, “bolt‑on” acquisitions rather than mega‑mergers, choosing focused science over sheer scale. The emphasis on allergy, oncology and CNS tracks with broader expectations that biopharma M&A will accelerate through 2026 as companies confront a roughly $170 billion patent cliff and look to replenish top‑line growth with late‑stage and de‑risked assets.
For biotech founders and investors, the message is clear: platforms that can credibly bend the curve in high‑value disease areas are still very much in demand, even if deal premiums are now negotiated with a bit more sobriety than in prior cycles. And for public‑market investors trying to handicap the next target, this week’s tape offers a familiar but still powerful script—follow the cash, follow the data, and watch closely whenever a late‑stage asset starts looking more like a revenue line than a research project.
Want to Learn More Now?
NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets.
At the same time, note that if radiopharma once sat in the “interesting, but niche” bucket, recent M&A has moved it firmly into the “board‑mandated strategic priority” column. Over roughly eight months, big pharma snapped up at least four of the sector’s hottest names: Novartis (NVS) acquired Mariana Oncology for around 1 billion dollars, Eli Lilly (LLY) bought Point Biopharma for about 1.4 billion dollars, AstraZeneca (AZN) purchased Fusion Pharmaceuticals for roughly 2.4 billion dollars, and Bristol Myers Squibb (BMY) acquired RayzeBio for approximately 4.1 billion dollars.
Learn more at this link:
Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )
The Sources
[1] Healthcare News, Deals, and Investments Update Mar 30th, 2026 https://www.lawrenceevans.com/2026/03/30/healthcare-news-deals-and-investments-update-mar-30th-2026/
[2] 2026 Biotech M&A Tracker: Deals, Upfronts, Totals & More – BioBucks https://www.biobucks.co/p/biotech-ma-tracker-2026
[3] Biotechnology Weekly Update – March 31, 2026 – YouTube https://www.youtube.com/watch?v=kYIjL4LIllw
[4] Recordati sizes up €10.9bn CVC Capital acquisition offer – ChemDiv https://www.chemdiv.com/company/media/pharma-news/2026/recordati-considers-10-9b-cvc-capital-acquisition-offer-before-q1-close/
[5] Big Pharma race to snap up biotech assets as $170 billion patent … https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
[6] Goodwin Advises Transcend Therapeutics on IP Aspects of its … https://www.goodwinlaw.com/en/news-and-events/news/2026/03/announcements-lifesciences-goodwin-advises-transcend-therapeutics
[7] Major M&A deals impacting bioanalysis in 2026 https://www.bioanalysis-zone.com/major-ma-deals-impacting-bioanalysis-in-2026/
[8] Top 10 Takeover Targets of 2026 https://www.genengnews.com/a-lists/top-10-takeover-targets-of-2026/
[9] Five things for pharma marketers to know for Monday, March 30, 2026 https://www.mmm-online.com/news/five-things-for-pharma-marketers-to-know-for-monday-march-30-2026/
[10] Biotech M&A is accelerating. Track the deals that are happening here. https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/
[11] Novo Nordisk Enters $2.1 Billion Partnership with Vivtex, GSK … https://www.pharmexec.com/view/mergers-acquisitions-roundup-novo-nordisk-enters-2-billion-partnership-vivtex-gsk-enters-950-million-acquisition-35pharma-inc-
[12] Pharmaceuticals, Biotechnology and Diagnostics M&A Agreements … https://finance.yahoo.com/news/pharmaceuticals-biotechnology-diagnostics-m-agreements-160200400.html
[13] Inside One Fund’s $170 Million Bet on a Biotech Stock Up 1,040% in … https://finance.yahoo.com/news/inside-one-funds-170-million-144806778.html
[14] 2026 biotech deals tracker: the latest partnerships and M&A https://www.labiotech.eu/biotech-deals-2026/
[15] Pharmaceuticals and Biotechnology Asset Purchase Agreements … https://finance.yahoo.com/news/pharmaceuticals-biotechnology-asset-purchase-agreements-154600470.html
